1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

Awaiting Word From AbbVie On Option Exercise

 
• By Mandy Jackson

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

Woman applying eye drops on light background, closeup
Reproxalap's rapid efficacy may be differentiating in dry eye disease • Source: Shutterstock

Aldeyra Therapeutics, Inc. plans to resubmit reproxalap for US Food and Drug Administration approval to treat dry eye disease based on the positive outcome of a Phase III dye eye chamber clinical trial that the agency required before it would reconsider the company’s new drug application (NDA). Aldeyra plans to refile the NDA before the end of 2024 and expects a six-month review as it promised investors back in March when the FDA cleared the design of its chamber trial design.

Key Takeaways

  • Aldeyra reported Phase III data from a dry eye chamber study that will support resubmission of reproxalap to the US FDA.

The agency issued a complete response letter (CRL) in November 2023, denying approval of reproxalap, a reactive aldehyde species (RASP)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Ophthalmology

Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD

 
• By Alaric DeArment

The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.

Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing

 
• By Lisa Takagi

The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED

 
• By Alaric DeArment

Results from the Phase III THRIVE trial in active thyroid eye disease had analysts calling veligrotug “best-in-class” as they anticipate results from THRIVE-2 in chronic TED later this year.